Skip to content

Potential Diagnostic and Prognostic Value of microRNAs for the Patients of Acute Coronary Syndrome

Potential Diagnostic and Prognostic Value of microRNAs for the Patients of Acute Coronary Syndrome

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02755207
Enrollment
100
Registered
2016-04-28
Start date
2016-04-30
Completion date
2020-12-31
Last updated
2020-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Coronary Syndrome

Brief summary

The purpose of this study is to evaluate the potential diagnostic and prognosis value of circulating microRNAs compared with cTnI for suspected ACS patients at the emergency department (ED) and intensive care unit (ICU).

Detailed description

The present study is a single-center, prospective diagnostic study among patients presenting to the ED or ICU within 24 h of onset of chest pain suggestive of suspected ACS. We propose to construct the biobank of ACS and evaluate the potential diagnostic value of circulating microRNAs compared with cTnI for suspected ACS patients. All the patients are to be followed up for 6 months. Final diagnosis was made by an expert panel cardiologist, based on all available clinical information including cTnI measurements, ECG, coronary angiography, cardiac exercise tests and information from hospital discharge letters. The concentrations of microRNAs will be evaluated by quantitative reverse transcription PCR, using highly specific primers and hybridization probes.

Interventions

None listed

Sponsors

Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
Yes

Inclusion criteria

Suspected ACS patients (STEMI, NSTEMI, and UA): Age\>18 years; Informed consent.

Exclusion criteria

Patients who will undergo immediate PCI; Pregnant and lactating women; Patients with mental disorders; Patients are using other experimental drugs; Refusal to provide informed.

Design outcomes

Primary

MeasureTime frame
Evaluate the diagnostic value of microRNAs in qPCR,in ACSDay 7

Secondary

MeasureTime frame
Evaluate the prognostic value of microRNAs in ACS6 months

Countries

China

Contacts

Primary Contactbin he
hebinicu@139.com
Backup Contacthuimin cao
150128433@qq.com

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026